AHR and neoplasm: Inhibitors of the IDO1‐KYN‐AHR pathway have been shown to alleviate the negative effects of Carboxyamidotriazole, a chemotherapeutic agent, against CD8+ T cells and produce supplementary useful pre‐tumour immunological effects.177